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Abstract
7-Amino-3,4-dihydro-1H-quinolin-2-one, a compound structurally similar to coumarins, recently
discovered class of inhibitors of the a-carbonic anhydrases (CAs, EC 4.2.1.1) was investigated for
its interaction with all human (h) CA isoforms, hCA I-XIV. The compound was not an inhibitor of
the cytosolic, widespread isoform hCA II (KI410 mM), was a weak inhibitor of hCA I, III, IV, VA, VI
and XIII (KIs in the range of 0.90–9.5 mM) but effectively inhibited the cytosolic isoform hCA VII
(KI of 480 nM) as well as the transmembrane isoforms hCA IX, XII and XIV (KIs in the range of
16.1–510 nM). Against many CA isoforms this lactam was a better inhibitor compared to the
structurally similar 4-methyl-7-aminocoumarin, but unlike this compound, the lactam ring was
not hydrolyzed and the inhibition was due to the intact bicyclic amino-quinolinone scaffold.
Bicyclic lactams strucurally related to coumarins are thus a new class of CA inhibitors possessing
however a distinct inhibition mechanism compared to the coumarins which undergo a
hydrolysis of their lactone ring for generating the enzyme inhibitory species.
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Introduction
Carbonic anhydrases (CAs, EC 4.2.1.1)1–5 are among the
fundamental catalysts found in nature, as they catalyze the
hydration of CO2 to bicarbonate and protons, being thus involved
in all processes connected to pH regulation, chemosensing (of
CO2, bicarbonate, acidity, etc.), several biosynthetic pathways,
electrolyte secretion in many tissues, and other physiological
processes6–15. It is thus not unexpected that at least six genetically
diverse CA families were described in organisms all over the
phylogenetic tree, the a-, b-, g-, d-, z- and Z-classes, which are
involved in crucial physiologic and pathologic processes in these
organisms16–21. In fact interference with the activity of these
enzymes has important physiologic consequences which were
exploited clinically by more than 65 years, by the use of the CA
inhibitors (CAIs)22–33. Sulfonamides22 constitute the main class of
CAIs and they are in clinical use as antiglaucoma agents23–28,
diuretics29, anti-obesity drugs30,31, and for the management of
hypoxic tumors which overexpress some CA isoforms2–5,32,33.
Such multiple applications of the CAIs are due to the fact
that in vertebrates 16 different CA isoforms are known1–5,
which are found in different tissues and organs, play diverse
physiologic functions, and their inhibition/activation elicits
different responses which are thus amenable to pharmacologic
modulation1–5,23–33.
Furthermore, in recent years these enzymes were isolated and
characterized in many pathogenic bacteria, protozoa and fungi,
and a possible use as anti-infectives emerged for the CAIs18,34–39.
However the main challenge for using CAIs of the sulfonamide
type in clinical settings is related to their off-target effects: the
first generation such drugs (acetazolamide, methazolamide,
dichorophenamide, ethoxzolamide, etc.) indiscriminately inhibit
most of the mammalian CA isoforms (including the human (h)
ones, hCAs), leading sometimes to serious side effects1–5,40–42. It
is thus understandable that many alternative classes of CAIs were
investigated recently, apart the sulfonamides. For example the
dithiocarbamates43 were discovered to act as CAIs, with a
mechanism of action related to that of the sulfonamides, as both
classes of derivatives coordinate to the metal ion from the enzyme
active site and replace the water molecule/hydroxide ion acting as
nucleophile in the catalytic cycle of these enzymes1–5,
However some of the most interesting new chemotypes
discovered ultimately to act as CAIs are undoubtedly the
coumarins/thiocoumarins (and compounds structurally related to
them, such as monocyclic five-/six-ring membered lactones)44–51
as well as the structurally related sulfocoumarins52–55. These
classes of CAIs possess a completely different inhibition mech-
anism compared to all other inhibitors investigated earlier, as
demonstrated by detailed kinetic and X-ray crystallographic
studies44,45,52. Indeed, the coumarins act as pro-drug inhibitors,
being hydrolyzed by the esterase activity of the CAs within the
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active site cavity with formation of carboxylic acids which
thereafter inhibit the enzyme by blocking the access to the active
site. Indeed, the binding site of this class of CAIs has never been
observed for any other class of inhibitors, being situated at the
entrance of the enzyme active site44,45. On the other hand, the
structurally related sulfocoumarins, in which the lactone CO
moiety of the coumarin was replaced by an SO2 group, are also
acting as pro-drug inhibitors, leading after hydrolysis to sulfonic
acid derivatives52. Unlike the hydrolyzed coumarins, the hydro-
lyzed sulfocoumarins bind more internally within the active site,
but again they do not directly interact with the zinc ion of the
enzyme. Like phenols56 and polyamines57, the sulfonic acids
formed by hydrolysis of the sulfocoumarins anchor by means of
hydrogen bonds to the zinc-coordinated water molecule which
acts as nucleophile in the catalytic process52. But what is even
more remarkable about these new classes of CAIs is that they
show an excellent selectivity profile for inhibiting various CA
isoforms of medicinal interest. For example among the substituted
coumarins, derivatives selective for all isoforms were detected,
with selectivity ratios for inhibiting the desired isoform over all
other human ones of 41000 (never observed with sulfonamide
CAIs)44–51. For sulfocumarins, derivatives with an excellent
selectivity for inhibiting the tumor associated isoforms hCA IX
and XII over the cytosolic ones hCA I and II were detected52,54,55,
in several series of compounds, together with a series of such
derivatives which selectively inhibited hCA II over the other
isoforms53, These interesting selectivity profiles for inhibiting
some and not other CA isoforms was explained by the inhibition
mechanism of these derivatives which implies on one hand a
hydrolytic process of the pro-drug inhibitor (which can be
kinetically diverse among the different isoforms, based on their
efficacy as esterases) and also due to the binding sites of the
formed inhibitors of the carboxylic/sulfonic acid type. As
mentioned above these inhibitors bind towards the external
regions of the CA active site, which differ among the diverse
isoforms, i.e. a larger number of non-conserved amino acid
residues are present in those regions of the active site and not in
the neighborhood of the zinc ion, where the sulfonamides
and similar zinc binders are found in the enzyme-inhibitor
adducts1–5,44,45,52.
Considering all these interesting aspects related to the
coumarin-type CAIs, here we explore other chemotypes structur-
ally related to them, and include in our study a bicyclic lactam
derivative, structurally rather similar to coumarins, i.e. 7-amino-
3,4-dihydro-1H-quinolin-2-one. This compound has been assayed
for the inhibition of all human CA isoforms with catalytic activity,
hCA I - hCA XIV.
Materials and methods
Chemistry
Compounds 1, 2 and acetazolamide (AAZ) used here were
commercially available from Sigma-Aldrich, Milan, Italy.
CA inhibition
A stopped-flow instrument (SX.18MV-R Applied Photophysics
model) was used for assaying the CA-catalyzed CO2 hydration
activity58. Inhibitor and enzyme were preincubated for 6 h (for 1
and 2)44,45 and 15 min (for AAZ) for allowing the complete
formation of the enzyme-inhibitor adduct. IC50 values were
obtained from dose response curves working at seven different
concentrations of test compound (from 0.1 nM to 50 mM), by
fitting the curves using PRISM (www.graphpad.com) and non-
linear least squares methods, the obtained values representing the
mean of at least three different determinations59. The inhibition
constants (KI) were derived from the IC50 values by using the
Cheng-Prusoff equation, as follows: Ki¼ IC50/(1 + [S]/Km) where
[S] represents the CO2 concentration at which the measurement
was carried out, and Km the concentration of substrate at which
the enzyme activity is at half maximal. All enzymes used were
recombinant, produced in E. coli as reported earlier59,60. The
concentrations of enzymes used in the assay were in the range of
8.5–12.7 nM.
Results and discussion
In the present paper we investigated the hCA I – hCA XIV
inhibitory properties of the lactam 1, 7-amino-3,4-dihydro-1H-
quinolin-2-one, a compound bearing structural similarity with the
coumarins. As coumarin counterpart we included compound 2, 4-
methyl-7-aminocoumarin, in our study as well as the standard
sulfonamide inhibitor acetazolamide (AAZ), a clinically used and
potent, non-selective CAI1–5.
Both derivatives 1 and 2 possess a bicyclic ring system, of the
lactam type in 1 and of the lactone type in 2. They also share as a
common feature the presence of an amino moiety in position 7 of
the ring, but the coumarin 2 is an aromatic derivative whereas the
lactam 1 has a saturated ring, as main distinction between them.
Furthermore, the coumarin has a 4-methyl group which is not
present in 1, but we showed in earlier studies that small moieties
(H, Me, etc.) in position 4 of coumarins as CAIs do not
significantly change the inhibitory power of the corresponding
derivatives44,45.
Inhibition data with compounds 1, 2 an AAZ are shown in
Table 1. The following structure-activity relationship can be
drawn from data of Table 1:
(1) The lactam 1 did not significantly inhibit the wide-
spread cytosolic isoform hCA II (a target for anti-glaucoma
drugs23–28 but an offtarget when other apllications of the
CAIs are pursued1–5) showing a KI of 410 mM. This is not
such an unexpected finding, as we have reported similar
features for many coumarin and sulfocoumarin derivatives,
which did not significantly inhibit this isoform44–52,54,55.
Other isoforms which were not strongly inhibited by lactam 1
were hCA I, III and XIII (cytosolic isozymes), as well as
hCA IV and hCA VI (membrane associated and secreted
Table 1. Human CA isoforms inhibition data with compounds 1, 2 and
AAZ as standard, by a stopped-flow CO2 hydrase assay49.
N
H
O O OH2N
SO2NH2H2N S
NN
AcNH
1 2 AAZ
.
Isoform, KI, nM* 1 2 AAZ
hCA I 6120 5560 250
hCA II 410000 410000 12
hCA III 3950 8440 410000
hCA IV 9495 410000 74
hCA VA 904 7810 63
hCA VI 3900 5695 11
hCA VII 480 185 2.5
hCA IX 124 7640 25
hCA XII 16.1 9130 5.7
hCA XIII 3810 7830 17
hCA XIV 510 188 41
*Errors in the range of ± 10% of the reported data, from 3 different assays
(not shown).
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isoforms, respectively), for which inhibition constants in the
range of 3810–9495 nM were measured (Table 1). A slightly
better inhibitory power of 1 was observed for the mitochon-
drial isoform hCA VA, for which a KI of 904 nM was
registered. The best inhibitory power of the lactam was
observed against four isoforms, the cytosolic hCA VII and the
three transmembrane isoforms hCA IX, XII and XIV. Against
these enzymes the inhibition constant of 1 ranged between
16.1 and 510 nM. The best inhibited isoform was the tumor-
associated hCA XII (KI of 16.1 nM) followed by the second
tumor-associated isoform, hCA IX (KI of 124 nM). These
findings are indeed remarkable, as the lactam 1 is a highly
selective CAI for the tumor-associated isoforms, with very
poor or insignificant inhibitory power against the widespread
and diffuse isoforms hCA I and II. But what was even more
remarkable was the fact that no signs of hydrolytic processes
of compound 1 (in the presence of buffer alone, or buffer +
CA isoforms) could be evidenced, even after incubation
times as long as 24–48 h (data not shown).
(2) The coumarin 2 was also not inhibitory against hCA II (KI of
410mM), as we reported earlier in a study in which the CA I,
II, IX and XII inhibitory power of this compound was
investigated.51 Here we extend the earlier work to the
remaining hCA Isoforms. Indeed, many of the investigated
isoforms, such as hCA I, III, IV (KI of410mM), VA, VI, IX,
XII and XIII were poorly inhibited by coumarin 2, with
inhibition constants in the micromolar rage (5695–9130 nM,
Table 1). In fact only hCA VII and XIV were significantly
inhibited by 2, with inhibition constants of 185–188 nM. It
should however be mentioned, that derivatives of 7 in which
the amino moiety was derivatized by reactions with isocyan-
ates or acyl chlorides led to compounds with low nanomolar
inhibitory activity against hCA IX and XII, as shown in the
earlier report51. Thus, the inhibition profile of compounds 1
and 2, although structurally similar, is very different, which
may be another proof that their inhibition mechanism must
be different: the coumarin 2 is hydrolyzed by the esterase
activity of the CA isoforms and the open form (substituted
hydroxycinnamic acid) acts as inhibitor, whereas for the
lactam 1, the non-hydrolysed bicyclic compound is the
inhibitor per se. This may be due to the fact that no peptidase
activity was ever reported for the CAs, although they possess
an active site metal coordination quite similar to that of
effective proteases/peptidases such as for example the matrix
metalloproteinases (MMPs)61.
(3) Acetazolamide AAZ, a sulfonamide used clinically, is a pan-
CA inhibitor, with a very promiscuous inhibition profile
(Table 1)1–5. In fact only hCA III was not significantly
inhibited (KI of410 mM), hCA I was inhibited with medium
potency (KI of 250 nM) whereas the remaining nine isoforms
were powerfully inhibited by this sulfonamide, with KIs in
the range of 2.5–74 nM (Table 1). These results explain why
AAZ has a wide range of side effects when administered
as systemically acting antiglaucoma agent (Scheme 1)22–28.
Conclusions
We investigated 7-amino-3,4-dihydro-1H-quinoline-2-one, a com-
pound structurally similar to the coumarins, a recently discovered
class of inhibitors of the a-CAs, for its interaction with all
catalytically active CA isoforms, hCA I-XIV. The compound was
not an inhibitor of the cytosolic, widespread isoform hCA II
(KI410 mM), was a weak, micromolar inhibitor of hCA I, III, IV,
VA, VI and XIII (KIs in the range of 0.90–9.5 mM) but effectively
inhibited the cytosolic isoform hCA VII (KI of 480 nM) as well as
the transmembrane isoforms hCA IX, XII and XIV (KIs in the
range of 16.1–510 nM). Against many CA isoforms the lactam 1
was a better inhibitor compared to the structurally similar 4-
methyl-7-aminocoumarin 2, but unlike this compound, the lactam
ring was not hydrolyzed and the inhibition was due to the intact
bicyclic amino-quinolinone scaffold. Bicyclic lactams strucurally
related to coumarins are thus a new class of CA inhibitors
possessing however a distinct inhibition mechanism compared to
the coumarins which undergo a hydrolysis of their lactone ring for
generating the enzyme inhibitory species.
As no X-ray crystal structures are yet available for this lactam
complexed to a CA isoform, we can only hypothesize its
inhibition mechanism. Most probably the compound may show
an inhibition mechanism typical of phenols, polyamines and
hydrolyzed sulfocoumarins, which all anchor to the zinc-
coordinated water molecule/hydroxide ion52,56,57. Indeed, through
its lactam-lactim tautomers 1a–1b (Scheme 1), compound 1 may
anchor by means of hydrogen bonds to the zinc-coordinated water
molecule/hydroxide ion either through the C¼O moiety, or as the
phenols, through its OH group. Further investigations are needed
to verify these hypotheses, but it should be also noted that the
primary 7-amino group present in 1 is also amenable to
derivatization which may lead to even more interesting CAIs
belonging to this novel chemotype.
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